^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
BMS-986148
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
BMS
Drug class:
Tubulin inhibitor, Mesothelin-targeted antibody-drug conjugate
Related drugs:
Phase 1
Bristol-Myers Squibb
Completed
Last update posted :
03/19/2020
Initiation :
10/14/2016
Primary completion :
09/06/2017
Completion :
09/06/2017
MSLN
|
MSLN expression
|
BMS-986148
Share
